Sarah Cannon Research Institute at Tennessee Oncology | ClinicalTrials HQ

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenoma, breast adenocarcinoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma, uterine cancer, uterine disorder	Recruiting	Phase 1 / Phase 2	2026-10-07		NCT05579366
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-03-04		NCT03741127